These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38839135)

  • 1. Summary and Panel Discussion.
    Butler J; Rich J; Pessah-Pollack R; Anderson JE
    JACC Heart Fail; 2024 Jun; 12(6S):S10-S11. PubMed ID: 38839135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of SGLT2 Inhibitors in Patients With HF With and Without Type 2 Diabetes: An Endocrinologist's Perspective.
    Butler J; Pessah-Pollack R
    JACC Heart Fail; 2024 Jun; 12(6S):S4-S6. PubMed ID: 38839136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology of Heart Failure and the Discovery of the Cardioprotective Effects of SGLT2 Inhibitors.
    Butler J; Rich J
    JACC Heart Fail; 2024 Jun; 12(6S):S1-S3. PubMed ID: 38839134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing Patients on SGLT2 Inhibitors in Primary Care.
    Butler J; Anderson JE
    JACC Heart Fail; 2024 Jun; 12(6S):S7-S9. PubMed ID: 38839137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors.
    Vaduganathan M; Januzzi JL
    Am J Cardiol; 2019 Dec; 124 Suppl 1():S20-S27. PubMed ID: 31741436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 inhibitors may offer benefit beyond diabetes.
    Kang A; Jardine MJ
    Nat Rev Nephrol; 2021 Feb; 17(2):83-84. PubMed ID: 33361782
    [No Abstract]   [Full Text] [Related]  

  • 7. Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.
    Cheng JWM; Colucci V; Kalus JS; Spinler SA
    Ann Pharmacother; 2021 Feb; 55(2):252-260. PubMed ID: 32536199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism.
    Imran H; Nester W; Elgendy IY; Saad M
    Ann Med; 2020 Aug; 52(5):178-190. PubMed ID: 32393068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors.
    Mordi IR; Lang CC
    Heart Fail Clin; 2022 Oct; 18(4):529-538. PubMed ID: 36216483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 inhibitors in heart failure and type 2 diabetes: from efficacy in trials towards effectiveness in the real world.
    Marx N; Müller-Wieland D
    Eur Heart J; 2023 Jun; 44(24):2231-2233. PubMed ID: 37287082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The unexpected benefits of sodium glucose co-transporter 2 (SGLT2) Inhibitors.
    Chan CG; Stewart R
    N Z Med J; 2022 Aug; 135(1560):99-104. PubMed ID: 35999803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT2 inhibitors in people with and without T2DM.
    Khunti K
    Nat Rev Endocrinol; 2021 Feb; 17(2):75-76. PubMed ID: 33293703
    [No Abstract]   [Full Text] [Related]  

  • 13. Six lessons learned from the use of SGLT2 inhibitors in patients with heart failure.
    Packer M
    Nat Rev Cardiol; 2022 Aug; 19(8):499-500. PubMed ID: 35697778
    [No Abstract]   [Full Text] [Related]  

  • 14. Is It Time to Relitigate SGLT2 Inhibitor Dose for Heart Failure?
    Howlett JG
    Can J Cardiol; 2023 May; 39(5):662-664. PubMed ID: 36889381
    [No Abstract]   [Full Text] [Related]  

  • 15. DAPA-HF study: Are the benefits uniform across non-diabetic subgroups.
    Pareek A; Rajput R; Kumar Chopra H; Dharmadhikari S
    Indian Heart J; 2020; 72(5):469-470. PubMed ID: 33189217
    [No Abstract]   [Full Text] [Related]  

  • 16. Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial.
    Mordi NA; Mordi IR; Singh JS; Baig F; Choy AM; McCrimmon RJ; Struthers AD; Lang CC
    BMJ Open; 2017 Oct; 7(10):e018097. PubMed ID: 29042392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Commentary: SGLT2 inhibitors reduce mortality and heart failure in patients with type 2 diabetes mellitus-is metabolic reprogramming the mechanism for these favorable outcomes?
    Lazar HL
    J Thorac Cardiovasc Surg; 2022 Sep; 164(3):901-904. PubMed ID: 33812677
    [No Abstract]   [Full Text] [Related]  

  • 18. Sodium glucose cotransporter-2 inhibitors protect the cardiorenal axis: Update on recent mechanistic insights related to kidney physiology.
    van Ruiten CC; Hesp AC; van Raalte DH
    Eur J Intern Med; 2022 Jun; 100():13-20. PubMed ID: 35414444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes, in chronic heart failure, and in chronic kidney disease?
    Qiu M; Ding LL; Zhan ZL; Zhou HR
    Eur J Intern Med; 2021 May; 87():98-99. PubMed ID: 33485738
    [No Abstract]   [Full Text] [Related]  

  • 20. SGLT2 Inhibitors: From Antihyperglycemic Agents to All-Around Heart Failure Therapy.
    Anker SD; Usman MS; Butler J
    Circulation; 2022 Jul; 146(4):299-302. PubMed ID: 35877834
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.